XOMA Royalty (NASDAQ:XOMA) Stock Passes Above 200 Day Moving Average – Here’s Why

XOMA Royalty Corporation (NASDAQ:XOMA)’s stock price crossed above its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $30.13 and traded as high as $30.50. XOMA Royalty shares last traded at $30.25, with a volume of 76,544 shares.

Analyst Ratings Changes

A number of equities research analysts have weighed in on the stock. Zacks Research downgraded shares of XOMA Royalty from a “hold” rating to a “strong sell” rating in a report on Tuesday, March 10th. Benchmark reaffirmed a “buy” rating on shares of XOMA Royalty in a research note on Friday, December 12th. Stifel Nicolaus set a $50.00 target price on shares of XOMA Royalty in a report on Friday, December 12th. Leerink Partners reissued an “outperform” rating on shares of XOMA Royalty in a research note on Tuesday, February 24th. Finally, HC Wainwright restated a “buy” rating and set a $97.00 target price on shares of XOMA Royalty in a report on Friday, March 20th. Three research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, XOMA Royalty currently has a consensus rating of “Hold” and a consensus price target of $61.60.

XOMA Royalty Price Performance

The stock has a 50-day moving average of $26.39 and a two-hundred day moving average of $30.13. The firm has a market cap of $360.16 million, a price-to-earnings ratio of 20.72 and a beta of 0.86. The company has a current ratio of 3.37, a quick ratio of 3.37 and a debt-to-equity ratio of 1.15.

XOMA Royalty (NASDAQ:XOMA) last posted its quarterly earnings data on Wednesday, March 18th. The biotechnology company reported $0.12 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.04) by $0.16. XOMA Royalty had a return on equity of 10.32% and a net margin of 45.75%.The firm had revenue of $13.76 million for the quarter, compared to the consensus estimate of $11.13 million. On average, analysts anticipate that XOMA Royalty Corporation will post -1.41 EPS for the current year.

Institutional Investors Weigh In On XOMA Royalty

Hedge funds have recently made changes to their positions in the company. Opaleye Management Inc. grew its position in XOMA Royalty by 14.7% during the 4th quarter. Opaleye Management Inc. now owns 292,590 shares of the biotechnology company’s stock worth $7,780,000 after purchasing an additional 37,503 shares in the last quarter. Woodline Partners LP lifted its holdings in shares of XOMA Royalty by 16.5% in the third quarter. Woodline Partners LP now owns 209,945 shares of the biotechnology company’s stock valued at $8,091,000 after purchasing an additional 29,715 shares in the last quarter. Vanguard Group Inc. lifted its holdings in shares of XOMA Royalty by 4.6% in the third quarter. Vanguard Group Inc. now owns 668,111 shares of the biotechnology company’s stock valued at $25,749,000 after purchasing an additional 29,298 shares in the last quarter. Stonepine Capital Management LLC boosted its position in shares of XOMA Royalty by 17.2% in the second quarter. Stonepine Capital Management LLC now owns 152,143 shares of the biotechnology company’s stock worth $3,834,000 after buying an additional 22,330 shares during the period. Finally, Occudo Quantitative Strategies LP acquired a new stake in shares of XOMA Royalty in the second quarter worth $527,000. Hedge funds and other institutional investors own 95.92% of the company’s stock.

XOMA Royalty Company Profile

XOMA Royalty (NASDAQ: XOMA) is a specialty healthcare royalty company that acquires and manages royalty interests in small-molecule and biologic drugs. The company’s business model centers on purchasing royalty streams on marketed or near-market pharmaceutical products, providing capital to developers in exchange for a share of future net sales. By focusing on late-stage assets with established clinical and commercial profiles, XOMA Royalty aims to generate predictable, long-term cash flows for its shareholders.

The company’s investment portfolio spans a range of therapeutic areas, including oncology, immunology and rare diseases.